New Drug, TASCENSO ODT[R] (fingolimod), Launched to Meet the Needs of Multiple Sclerosis Patients in the US Left Without Essential Patient Support
In: Business Wire, 2023-02-13
Zeitungsartikel
Zugriff:
Titel: |
New Drug, TASCENSO ODT[R] (fingolimod), Launched to Meet the Needs of Multiple Sclerosis Patients in the US Left Without Essential Patient Support
|
---|---|
Zeitschrift: | Business Wire, 2023-02-13 |
Veröffentlichung: | 2023 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|